The Register · A provider

Keio University School of Medicine

Tokyo · Japan

Specialties

psychedelic-assisted therapy research ketamine treatment research hematopoietic stem cell transplantation

Psychedelic Treatment Quality in Japan: Conducting Asia's first psilocybin clinical trial of the 21st century, funded by AMED. Led by Dr. Hiroyuki Uchida. Joint research agreement with Otsuka Pharmaceutical (May 2025) to develop psychedelic therapy infrastructure. Published Japanese cultural adaptations of psychedelic measurement instruments (MEQ30, CEQ) in 2024.
Stem Cell Transplant Quality in Japan